Modulation of mGluR1 signaling improves Purkinje cell dysfunction associated with spinocerebellar ataxia 14
简介:
- 作者: Zsófia Sziber, Shiqi Tang, Paula Torrents-Solé, Aleksandar Kovacevic, Josef P Kapfhammer
- 杂志: iScience
- Doi: 10.1016/j.isci.2026.117976
- 出版日期: 2026/11/20
摘要
Spinocerebellar ataxia type 14 (SCA14) is caused by mutations in protein kinase C gamma (PKCγ) that lead to constitutive kinase activity and Purkinje cell dysfunction in the cerebellum. PKCγ acts downstream of metabotropic glutamate receptor 1 (mGluR1) signaling; however, it remains unclear whether alterations in this upstream pathway contribute to the cellular defects induced by mutant PKCγ. Here, we investigated the role of mGluR1 signaling in PKCγ-dependent pathology using organotypic cerebellar slice cultures from a mouse model of SCA14. Modulation of mGluR1 signaling partially improved dendritic abnormalities and dendritic spine phenotypes associated with constitutive PKCγ activation. In addition, inhibition of mGluR1 reduced phosphorylation of PKC substrates and restored the enrichment of scaffold proteins and their synaptic proximity to mGluR1. Together, our results demonstrate that mGluR1 signaling contributes to Purkinje cell abnormalities induced by constitutive PKCγ activity and that modulation of mGluR1 can improve disease-associated cellular phenotypes in SCA14.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。